Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Current Opinion in Pharmacology, 3(13), p. 435-439

DOI: 10.1016/j.coph.2013.02.002

Links

Tools

Export citation

Search in Google Scholar

The bisphosphonates: Risks and benefits of long term use

Journal article published in 2013 by Anne Pernille Hermann, Bo Abrahamsen ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Bisphosphonates are widely used globally as the main treatment for osteoporosis. Both safety and efficacy have only been rigorously evaluated in studies of relatively short duration (3-5 years), with smaller extension studies. The evidence for benefit beyond five years in intervention studies is limited and does not include proven efficacy against nonvertebral fractures. Observational studies suggest a sustained benefit against hip fractures. Bisphosphonates are stored in the skeleton for months to years, depending on the degree of bone turnover and the binding properties of the bisphosphonate in question. The effects of continued treatment on bone strength is not known but there are concerns that osteonecrosis of the jaw and atypical femur fractures may stem from long term bisphosphonate use.